Study of RVT-1401 for the Treatment of Patients With Moderate to Severe Active Graves' Ophthalmopathy | oneGRAVESvoice
Global Search
Global Search

Trusted Resources: Evidence & Education

Scientific literature and patient education texts

Back to Evidence & Education / Reference Materials

Study of RVT-1401 for the Treatment of Patients With Moderate to Severe Active Graves’ Ophthalmopathy

key information

source: U.S. National Library of Medicine

year: 2021

summary/abstract:

The purpose of the current study is to confirm safety/tolerability and key pharmacodynamic (PD) effects that are considered to drive clinical benefit in GO patients. 

 

Primary Outcome Measure: 

• Assessment of safety by analysis of adverse events (AEs) data [ Time Frame: 7 Weeks ] AE summaries of the number and percent of participants reporting each event at least once will be generated. Other safety data will be summarized descriptively.

• Percentage change from baseline in total IgG and IgG subclasses (1-4) [ Time Frame: 7 Weeks ]

• Percentage change in levels of anti-TSHR antibodies [ Time Frame: 7 Weeks ]

 

Secondary Outcome Measure:

• Percent change from baseline in proptosis [ Time Frame: 7 Weeks ]

• Total number of proptosis responders [ Time Frame: 7 Weeks ]

• Pharmacokinetics (PK) Parameters of AUC (0-168 h) after first and last dose [ Time Frame: 7 Weeks ]

• Pharmacokinetics (PK) maximum concentration (Cmax) after first and last dose [ Time Frame: 7 Weeks ]

• Concentration of RVT-1401 pre-dose (Ctrough) [ Time Frame: 7 Weeks ]

• Immunogenicity determined by number of participants with positive anti-RVT-1401 antibodies and characterization of any anti-RVT-1401 antibodies to confirm neutralization potential [ Time Frame: 7 Weeks ]

 

read more

Related Content

To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close

Powered by

Brought to you by

Supported through an independent
educational grant by

© 2022 rareLife solutions Inc.